Renalytix annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Renalytix Stock-Based Compensation Growth & History (RENX)
Renalytix's stock-based compensation was $3.2M for fiscal 2025.
View full Renalytix company overviewRenalytix annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $3.2M | $1.5M | +87.13% |
| 2024 | 2024-06-30 | $1.7M | −$1.2M | −41.68% |
| 2023 | 2023-06-30 | $2.9M | −$1.7M | −36.55% |
| 2022 | 2022-06-30 | $4.6M | $2.0M | +73.53% |
| 2021 | 2021-06-30 | $2.7M | $1.5M | +129.77% |
| 2020 | 2020-06-30 | $1.2M | $634,000 | +120.76% |
| 2019 | 2019-06-30 | $525,000 | — | — |
Renalytix quarterly stock-based compensation
Q3.21
Q1.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2024-12-31 | $73,000 | −$313,000 | −81.09% |
| Q1 2025 | 2024-09-30 | $254,000 | −$269,000 | −51.43% |
| Q4 2024 | 2024-06-30 | $419,000 | −$155,000 | −27.00% |
| Q3 2024 | 2024-03-31 | $382,000 | −$392,000 | −50.65% |
| Q2 2024 | 2023-12-31 | $386,000 | −$431,000 | −52.75% |
| Q1 2024 | 2023-09-30 | $523,000 | −$244,000 | −31.81% |
| Q4 2023 | 2023-06-30 | $574,000 | — | — |
| Q3 2023 | 2023-03-31 | $774,000 | −$149,000 | −16.14% |
| Q2 2023 | 2022-12-31 | $817,000 | — | — |
| Q1 2023 | 2022-09-30 | $767,000 | −$230,000 | −23.07% |
| Q3 2022 | 2022-03-31 | $923,000 | $922,389 | +150963.83% |
| Q1 2022 | 2021-09-30 | $997,000 | — | — |
| Q3 2021 | 2021-03-31 | $611 | — | — |
Renalytix stock-based compensation trends
Over the last five fiscal years, Renalytix's stock-based compensation increased from $1.2M to $3.2M, a change of $2.0M. The latest reported quarter, Q2 2025, shows $73,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Renalytix source filings ↗